TRABIHealthcare Service Provider
Transgene Biotek Ltd — Cash Flow Statement
₹1.98
-2.15%
Transgene Biotek Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -0.50 Cr | 46000.00 | -13000.00 | 0.10 Cr | — |
| Repayment Of Debt | -4.98 Cr | — | 0.00 | 0.00 | 0.00 |
| Issuance Of Debt | 6.00 Cr | — | 0.00 | — | — |
| Capital Expenditure | -1.70 Cr | — | -15000.00 | — | -0.03 Cr |
| End Cash Position | 0.28 Cr | 77000.00 | 31000.00 | 0.02 Cr | — |
| Beginning Cash Position | 77000.00 | 31000.00 | 0.02 Cr | 0.01 Cr | — |
| Changes In Cash | 0.28 Cr | 46000.00 | -0.01 Cr | 9485.00 | — |
| Financing Cash Flow | 0.78 Cr | 0.00 | 0.00 | 0.00 | — |
| Net Other Financing Charges | -1000.00 | — | — | — | — |
| Interest Paid Cff | -0.24 Cr | — | — | — | — |
| Net Issuance Payments Of Debt | 1.02 Cr | — | 0.00 | 0.00 | 0.00 |
| Net Long Term Debt Issuance | 1.02 Cr | — | 0.00 | 0.00 | 0.00 |
| Long Term Debt Payments | -4.98 Cr | — | 0.00 | 0.00 | 0.00 |
| Long Term Debt Issuance | 6.00 Cr | — | 0.00 | — | — |
| Investing Cash Flow | -1.70 Cr | 0.00 | -0.01 Cr | -0.10 Cr | — |
| Capital Expenditure Reported | -1.70 Cr | 0.00 | -15000.00 | 0.00 | — |
| Operating Cash Flow | 1.20 Cr | 46000.00 | 2000.00 | 0.10 Cr | — |
| Change In Working Capital | 1.72 Cr | 0.61 Cr | 1.05 Cr | 0.52 Cr | — |
| Change In Other Current Liabilities | 0.68 Cr | 0.69 Cr | 0.75 Cr | 0.59 Cr | — |
| Change In Other Current Assets | 0.12 Cr | -0.06 Cr | -0.19 Cr | 0.02 Cr | — |
| Change In Payable | 1.40 Cr | -0.03 Cr | 0.03 Cr | -0.04 Cr | — |
| Change In Inventory | -1000.00 | -1000.00 | 0.06 Cr | -0.07 Cr | — |
| Other Non Cash Items | 0.07 Cr | -0.05 Cr | 60000.00 | 0.05 Cr | — |
| Depreciation And Amortization | 0.09 Cr | 0.09 Cr | 4.95 Cr | 9.92 Cr | — |
| Depreciation | 0.09 Cr | 0.09 Cr | 4.95 Cr | 9.92 Cr | — |
| Net Income From Continuing Operations | -0.68 Cr | -0.66 Cr | -6.01 Cr | -10.40 Cr | — |
| Effect Of Exchange Rate Changes | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Business Purchase And Sale | — | 0.00 | 0.00 | -0.10 Cr | 0.00 |
| Purchase Of Business | — | 0.00 | 0.00 | -0.10 Cr | 0.00 |
| Taxes Refund Paid | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Amortization Cash Flow | — | 72000.00 | — | — | — |
| Gain Loss On Sale Of PPE | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash Adjustment Outside Changein Cash | — | — | 1000.00 | — | 1.00 |
| Net Other Investing Changes | — | — | -0.01 Cr | -18392.00 | — |
| Net Investment Purchase And Sale | — | — | 0.00 | -0.10 Cr | — |
| Change In Receivables | — | — | 0.00 | — | 0.00 |
| Issuance Of Capital Stock | — | — | — | — | 10.00 |
| Net Common Stock Issuance | — | — | — | — | 10.00 |
| Common Stock Issuance | — | — | — | — | 10.00 |
| Net PPE Purchase And Sale | — | — | — | — | 0.00 |
| Sale Of PPE | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Transgene Biotek Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.